Synlogic (SYBX) Stock Price, News & Analysis

Company Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.21 to $1.25
• 50-Day Range: $1.01 to $1.28
• 52-Week Range: $0.90 to $1.88
• Volume: 2,231 shs
• Average Volume: 17,904 shs
• Market Capitalization: $14.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Synlogic Stock Analysis - MarketRank™

Synlogic scored higher than 18% of companies evaluated by MarketBeat, and ranked 1691st out of 1,880 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Synlogic.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Synlogic are expected to grow in the coming year, from ($2.71) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Synlogic is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synlogic is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synlogic has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.51% of the float of Synlogic has been sold short.

Short Interest Ratio / Days to Cover

Synlogic has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synlogic has recently increased by 32.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synlogic does not currently pay a dividend.

Dividend Growth

Synlogic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.51% of the float of Synlogic has been sold short.

Short Interest Ratio / Days to Cover

Synlogic has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synlogic has recently increased by 32.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Synlogic has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Synlogic this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for SYBX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synlogic insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.02% of the stock of Synlogic is held by insiders.

Percentage Held by Institutions

63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SYBX Stock Analysis - Frequently Asked Questions

How have SYBX shares performed this year?

Synlogic's stock was trading at $1.40 on January 1st, 2025. Since then, SYBX stock has decreased by 12.1% and is now trading at $1.23.
View the best growth stocks for 2025 here.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings data on Thursday, March, 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04.

When did Synlogic's stock split?

Synlogic's stock reverse split on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Reata Pharmaceuticals (RETA), Sangamo Therapeutics (SGMO), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 6/17/2025
• Next Earnings (Estimated): 6/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYBX
• CIK: 1527599
• Web: www.synlogictx.com
• Phone: (617) 401-9975
• Fax: 512-681-5201
• Employees: 80
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($2.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: -291,924.97%
• Return on Equity: 10.91%
• Return on Assets: 7.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.68
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,439.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 1.13

Miscellaneous

• Outstanding Shares: 11,700,000
• Free Float: 11,343,000
• Market Cap: $14.39 million
• Optionable: Optionable
• Beta: 0.51